BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38338342)

  • 1. Hexane Fraction of
    Park HJ; Jeong JH; Choi YH; Park SH
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hexane fraction of
    Park HJ; Park SH
    Nat Prod Res; 2023; 37(17):2924-2928. PubMed ID: 36305751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
    Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
    J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extract of Polygoni Cuspidati Rhizoma et Radix suppresses the vascular endothelial growth factor-induced angiogenesis.
    Hu WH; Chan GK; Lou JS; Wu QY; Wang HY; Duan R; Cheng MY; Dong TT; Tsim KW
    Phytomedicine; 2018 Mar; 42():135-143. PubMed ID: 29655679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asiatic acid inhibits angiogenesis and vascular permeability through the VEGF/VEGFR2 signaling pathway to inhibit the growth and metastasis of breast cancer in mice.
    Tian M; Chen K; Huang J; Chu D; Li J; Huang K; Ma C
    Phytother Res; 2021 Nov; 35(11):6389-6400. PubMed ID: 34541711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
    Cho HD; Lee KW; Won YS; Kim JH; Seo KI
    J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model.
    Wen Jun L; Pit Foong C; Abd Hamid R
    Biomed Pharmacother; 2019 Oct; 118():109221. PubMed ID: 31545225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The crosstalk between lung cancer cells and platelets promotes tumor angiogenesis in vivo and in vitro.
    Li B; Zhu T; Wu X; Chen S; Lu C; Zhu J; Li Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3495-3511. PubMed ID: 35951091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
    Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY
    Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
    Han L; Wang JN; Cao XQ; Sun CX; Du X
    Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
    Lin SW; Huang SC; Kuo HM; Chen CH; Ma YL; Chu TH; Bee YS; Wang EM; Wu CY; Sung PJ; Wen ZH; Wu DC; Sheu JH; Tai MH
    Mar Drugs; 2015 Feb; 13(2):861-78. PubMed ID: 25668036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murrangatin suppresses angiogenesis induced by tumor cell-derived media and inhibits AKT activation in zebrafish and endothelial cells.
    Long W; Wang M; Luo X; Huang G; Chen J
    Drug Des Devel Ther; 2018; 12():3107-3115. PubMed ID: 30288018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.